Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
[Skip to Navigation] JAMA Oncol. 2023;9(3):436-437. doi:10.1001/jamaoncol.2022.7361 Full Text In Reply We thank Reni et al for their interest in the PRODIGE 24/Canadian Cancer Trials Group PA6 randomized clinical trial.1 We agree that modified FOLFIRINOX (mFOLFIRINOX) has intrinsic toxicity, but it is manageable and even better maintained quality of life compared with gemcitabine in the metastatic setting.2 Full Text
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
